Melero et al. [12] first demonstrated the use of agonistic anti-4-1BB antibodies as a cancer therapy and this approach has now moved to phase I clinical trials for advanced cancers (http://www.clinicaltrials.gov keyword CD137). The gene discussed is TNFRSF9; the disease is cancer.